Annals of Oncology 12:981-986, 2001
© 2001 European Society for Medical Oncology
research-article |
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia
1University and Inselspital, Department of Clinical Research, Medical Oncology/Haematology Berne. Switzerland
2Charite/Virchow-Clinic, Humboldt-University, Department of Haematology/Oncology Berlin, Germany
M. F. Fey. MD Institute of Medical Oncology University of Berne. Inselspital 3010 Berne Switzerland E-mail: martin.fey{at}insel.ch
The p73 protein shares structural and functional similarities with the tumour-suppressor p53, but its role in neoplastic transformation is unknown. Alternative splicing leads to the expression of at least nine p73 C-terminal mRNA splice variants (
ß 
l 
). In this survey, we analyse the expression of p73 by real-time quantitative RT-PCR, its known C-terminal variants with an RT-PCR-Southern tech nique and by Western blot in samples of 51 patients with B-CLL, normal B lymphocytes from eight individuals, and five haematopoetic cell lines. p73 protein expression positively correlated with higher risk B-CLL stages (P=0.046).
Total p73 mRNA expression was higher (P= 0.01) and p73 protein more frequently detected (P=0.008) in B-CLL compared with normal CD19+—B-lymphocytes. p73 C-terminal mRNA variants were expressed both in B-CLL and in normal B-lymphocytes, but their expression was biased since the (P=0.041), the (P << 0.001), and the variant (P=0.033) prevailed in normal B-lymphocytes. In summary, we conclude that the accumulation of p73, the expression pattern of particular p73 variants and its link to progression may play a distinct role in the molecular pathology B-CLL.
apoptosis, B-CLL, overexpression, p53, p73
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. K. Ahmad, X. Altuna, J. P. Lopez, Y. An, J. Wang-Rodriguez, V. R. Juneja, J. S. Chen, M. J. Arandazi, J. Aguilera, J. P. Harris, et al. p73 Expression and Function in Vestibular Schwannoma Arch Otolaryngol Head Neck Surg, July 1, 2009; 135(7): 662 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dicker, A. P. Kater, C. E. Prada, T. Fukuda, J. E. Castro, G. Sun, J. Y. Wang, and T. J. Kipps CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53 Blood, November 15, 2006; 108(10): 3450 - 3457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Guan and Y Chen Aberrant expression of {Delta}Np73 in benign and malignant tumours of the prostate: correlation with Gleason score J. Clin. Pathol., November 1, 2005; 58(11): 1175 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Nyman, A. Sobczak-Pluta, P. Vlachos, T. Perlmann, B. Zhivotovsky, and B. Joseph Full-length p73{alpha} Represses Drug-induced Apoptosis in Small Cell Lung Carcinoma Cells J. Biol. Chem., October 7, 2005; 280(40): 34159 - 34169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stiewe, S. Tuve, M. Peter, A. Tannapfel, A. H. Elmaagacli, and B. M. Putzer Quantitative TP73 Transcript Analysis in Hepatocellular Carcinomas Clin. Cancer Res., January 15, 2004; 10(2): 626 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. M. Moll The Role of p63 and p73 in Tumor Formation and Progression: Coming of Age Toward Clinical Usefulness: Commentary re: F. Koga et al., Impaired p63 Expression Associates with Poor Prognosis and Uroplakin III Expression in Invasive Urothelial Carcinoma of the Bladder. Clin. Cancer Res., 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in Human Normal and Tumor Tissues: Loss of p73{alpha} Expression Is Associated with Tumor Progression in Bladder Cancer. Clin. Cancer Res., 9: 5642-5651, 2003. Clin. Cancer Res., November 15, 2003; 9(15): 5437 - 5441. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guan, H.-X. Peng, B. Yu, and Y. Lu p73 Overexpression and Angiogenesis in Human Colorectal Carcinoma Jpn. J. Clin. Oncol., May 1, 2003; 33(5): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Freebern, J. L. Smith, S. S. Chaudhry, C. M. Haggerty, and K. Gardner Novel Cell-specific and Dominant Negative Anti-apoptotic Roles of p73 in Transformed Leukemia Cells J. Biol. Chem., January 17, 2003; 278(4): 2249 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stiewe, S. Zimmermann, A. Frilling, H. Esche, and B. M. Putzer Transactivation-deficient {Delta}TA-p73 Acts as an Oncogene Cancer Res., July 1, 2002; 62(13): 3598 - 3602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stiewe, C. C. Theseling, and B. M. Putzer Transactivation-deficient Delta TA-p73 Inhibits p53 by Direct Competition for DNA Binding. IMPLICATIONS FOR TUMORIGENESIS J. Biol. Chem., April 12, 2002; 277(16): 14177 - 14185. [Abstract] [Full Text] [PDF]
|
|